An 84‐year‐old woman was admitted to our hospital because of worsening dyspnea and persistent fever. Her serum C‐reactive protein and soluble interleukin‐2 receptor levels were elevated as 18.57 U/L and 2113 U/mL, respectively. Chest computed tomography revealed pleural and cardiac effusions (Figure 1A). Pleurocentesis showed a pale‐bloody, yellowish exudative effusion, with findings of increased cells (monocyte‐dominant 880 cells/μL), elevated total protein (4.2 g/dL), and a presence of atypical lymphoid cells (Figure 1B). A cell‐block smear of the pleural effusion showed aggregation of CD‐3‐positive, CD‐20‐positive, Ki67‐positive, and EBV‐encoded small RNA (EBER)‐negative abnormal cells (Figure 1C‐G). Reactivation of human herpesvirus (HHV)‐8 was not confirmed due to the unavailability of the test in our setting. What is your diagnosis?
1 FIGURE. Chest computed tomography and pathological findings of pleural effusion. Cardiac and pleural effusions (A). Atypical lymphoid cells were identified in the pleural effusion by cytology (B) and cell‐block smear (C) (hematoxylin and eosin stain). Immunostaining revealed CD3 (D), CD20 (E), and Ki‐67 (F) positivity and EBV‐encoded small RNA (EBER, G) negativity. CD, cluster of differentiation; EBV, Epstein‐Barr virus
The patient was diagnosed with primary effusion lymphoma (PEL)‐like lymphoma. PEL is a rare non‐Hodgkin's lymphoma that is classified as a mature B‐cell neoplasm, which is associated with HHV‐8 infection and lacks CD20 expression because of plasmablastic differentiation.1‐3 In case HHV‐8 reactivation is not confirmed or related as this case, it is considered PEL‐like lymphoma. Differential diagnosis of the disease includes plasmablastic lymphoma or pyothorax‐associated lymphoma. A fluid smear is often of no use for the miscellaneous condition, whereas a cell‐block smear and immunostaining procedures potentially lead to a diagnosis.
Published with written consent of the patient
The authors state that there are no conflicts of interests to declare.
YS, KT, HH, and FO have contributed to the management of the patient and drafting of the manuscript.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Primary effusion lymphoma (PEL) is a kind of malignant lymphoma that develops without a tumor mass. A fluid smear is of no use for the diagnosis of miscellaneous condition. Repeated cell‐block smear with immunostaining is useful for the diagnosis of PEL.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer